Contact

All Stories

  1. Mast Cells as a Target—A Comprehensive Review of Recent Therapeutic Approaches

    Article • Cells, April 2023, MDPI AG

    Dr Lukasz Kuryk, MBA

  2. Data from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Lukasz Kuryk, MBA

  3. Data from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Lukasz Kuryk, MBA

  4. Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Lukasz Kuryk, MBA

  5. Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Lukasz Kuryk, MBA

  6. Supplementary Figures S1 to S7 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Lukasz Kuryk, MBA

  7. Supplementary Figures S1 to S7 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Lukasz Kuryk, MBA

  8. Supplementary Methods 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Lukasz Kuryk, MBA

  9. Supplementary Methods 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Lukasz Kuryk, MBA

  10. Supplementary Table 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Lukasz Kuryk, MBA

  11. Supplementary Table 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Lukasz Kuryk, MBA

  12. Oncolytic Adenoviruses Armed with Co-Stimulatory Molecules for Cancer Treatment

    Article • Cancers, March 2023, MDPI AG

    Dr Lukasz Kuryk, MBA

  13. Next generation of oncolytic viruses with the double transgenes PADI1 and TIMP-2 exhibit anti-tumor activity against melanoma in nude mouse and humanized NOG mouse models

    Article • Molecular Therapy — Oncolytics, January 2023, Elsevier

    Dr Lukasz Kuryk, MBA

  14. In vitro immune evaluation of adenoviral vector-based platform for infectious diseases

    Article • BioTechnologia, January 2023, Termedia Sp. z.o.o.

    Dr Lukasz Kuryk, MBA

  15. Development of mesothelioma-specific oncolytic vaccine exploiting immunopeptidomic analysis of murine and human tumors

    Article • November 2022, Research Square

    Dr Lukasz Kuryk, MBA

  16. Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor micro-environment and clinical outcomes in anti-PD1-resistant advanced melanoma

    Article • Clinical Cancer Research, September 2022, American Association for Cancer Research (AACR)

    Dr Lukasz Kuryk, MBA

  17. Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects

    Article • Frontiers in Oncology, June 2022, Frontiers

    Dr Lukasz Kuryk, MBA

  18. Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial

    Article • Journal of Asthma and Allergy, June 2022, Taylor & Francis

    Dr Lukasz Kuryk, MBA

  19. The Multifaceted Roles of Mast Cells in Immune Homeostasis, Infections and Cancers

    Article • International Journal of Molecular Sciences, February 2022, MDPI AG

    Dr Lukasz Kuryk, MBA

  20. Tetrazole derivatives bearing benzodiazepine moiety—synthesis and action mode against virulence of Candida albicans

    Article • European Journal of Medicinal Chemistry, February 2022, Elsevier

    Dr Lukasz Kuryk, MBA

  21. From Immunosuppression to Immunomodulation - Turning Cold Tumours into Hot

    Article • Journal of Cancer, January 2022, Ivyspring International Publisher

    Dr Lukasz Kuryk, MBA

  22. 368 Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors

    Article • Journal for ImmunoTherapy of Cancer, November 2021, BMJ

    Dr Lukasz Kuryk, MBA

  23. 462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data

    Article • Journal for ImmunoTherapy of Cancer, November 2021, BMJ

    Dr Lukasz Kuryk, MBA

  24. ESGCT 2021: Virtually Pan-European

    Article • Human Gene Therapy, October 2021, Mary Ann Liebert Inc

    Dr Lukasz Kuryk, MBA

  25. The Antifungal Action Mode of N-Phenacyldibromobenzimidazoles

    Article • Molecules, September 2021, MDPI AG

    Dr Lukasz Kuryk, MBA

  26. 1083P A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma

    Article • Annals of Oncology, September 2021, Elsevier

    Dr Lukasz Kuryk, MBA

  27. In Vitro Anti-Candida Activity and Action Mode of Benzoxazole Derivatives

    Article • Molecules, August 2021, MDPI AG

    Dr Lukasz Kuryk, MBA

  28. Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells

    Article • Pharmaceutics, June 2021, MDPI AG

    Dr Lukasz Kuryk, MBA

  29. Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model

    Article • Pharmaceutics, April 2021, MDPI AG

    Dr Lukasz Kuryk, MBA

  30. Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation

    Article • Nanotheranostics, January 2021, Ivyspring International Publisher

    Dr Lukasz Kuryk, MBA

  31. Antifungal polybrominated proxyphylline derivative induces Candida albicans calcineurin stress response in Galleria mellonella

    Article • Bioorganic & Medicinal Chemistry Letters, December 2020, Elsevier

    Dr Lukasz Kuryk, MBA

  32. 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes

    Article • November 2020, BMJ

    Dr Lukasz Kuryk, MBA

  33. From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review

    Article • Cancers, October 2020, MDPI AG

    Dr Lukasz Kuryk, MBA

  34. Abstract 4562: Next generation Oncos oncolytic adenovirus with novel anti-cancer double-transgenes shows synergistic anticancer effect in melanoma mouse model

    Article • Cancer Research, August 2020, American Association for Cancer Research (AACR)

    Dr Lukasz Kuryk, MBA

  35. Cover Image, Volume 92, Number 8, August 2020

    Article • Journal of Medical Virology, July 2020, Wiley

    Dr Lukasz Kuryk, MBA

  36. Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2

    Article • Vaccines, June 2020, MDPI AG

    Dr Lukasz Kuryk, MBA

  37. Steering the Clinical Translation of Delivery Systems for Drugs and Health Products

    Article • Pharmaceutics, April 2020, MDPI AG

    Dr Lukasz Kuryk, MBA

  38. 2020 ASGCT Annual Meeting Abstracts

    Article • Molecular Therapy, April 2020, Elsevier

    Dr Lukasz Kuryk, MBA

  39. Sulfone derivatives enter the cytoplasm of Candida albicans sessile cells

    Article • European Journal of Medicinal Chemistry, April 2020, Elsevier

    Dr Lukasz Kuryk, MBA

  40. Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein‐2 cell entry receptor

    Article • Journal of Medical Virology, February 2020, Wiley

    Dr Lukasz Kuryk, MBA

  41. Multiple KRAS mutations detected by cancer related DNA in patients with resected pancreas adenocarcinoma during treatment with TG01/GM-CSF and gemcitabine (CT TG01-01)

    Article • Annals of Oncology, December 2019, Elsevier

    Dr Lukasz Kuryk, MBA

  42. ESGCT 27th Annual Congress In collaboration with SETGyc Barcelona, Spain October 22–25, 2019 Abstracts

    Article • Human Gene Therapy, November 2019, Mary Ann Liebert Inc

    Dr Lukasz Kuryk, MBA

  43. 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2

    Article • Journal for ImmunoTherapy of Cancer, November 2019, Springer Science + Business Media

    Dr Lukasz Kuryk, MBA

  44. Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma

    Article • Journal of Medical Virology, June 2019, Wiley

    Dr Lukasz Kuryk, MBA

  45. Abstract A022: Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC)

    Article • Cancer Immunology Research, February 2019, American Association for Cancer Research (AACR)

    Dr Lukasz Kuryk, MBA

  46. Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks

    Article • International Journal of Molecular Sciences, January 2019, MDPI AG

    Dr Lukasz Kuryk, MBA

  47. Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice

    Article • Journal of Controlled Release, January 2019, Elsevier

    Dr Lukasz Kuryk, MBA

  48. Heterologous and cross-species tropism of cancer-derived extracellular vesicles

    Article • Theranostics, January 2019, Ivyspring International Publisher

    Dr Lukasz Kuryk, MBA

  49. Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model

    Article • OncoImmunology, October 2018, Taylor & Francis

    Dr Lukasz Kuryk, MBA

  50. Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies

    Article • Viruses, October 2018, MDPI AG

    Dr Lukasz Kuryk, MBA

  51. Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment

    Article • Journal of Controlled Release, August 2018, Elsevier

    Dr Lukasz Kuryk, MBA

  52. Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401

    Article • Cancer Gene Therapy, July 2018, Springer Science + Business Media

    Dr Lukasz Kuryk, MBA

  53. Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model

    Article • Journal of Medical Virology, June 2018, Wiley

    Dr Lukasz Kuryk, MBA

  54. Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment

    Article • PLoS ONE, August 2017, PLOS

    Dr Lukasz Kuryk, MBA

  55. Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

    Article • New England Journal of Medicine, June 2017, New England Journal of Medicine (NEJM/MMS)

    Dr Lukasz Kuryk, MBA

  56. A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma

    Article • OncoImmunology, May 2017, Taylor & Francis

    Dr Lukasz Kuryk, MBA

  57. Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model

    Article • International Journal of Cancer, June 2016, Wiley

    Dr Lukasz Kuryk, MBA

  58. 408. Oncolytic Vaccines in Combination with PD-L1 Blockade for the Treatment of Melanoma

    Article • Molecular Therapy, May 2016, Elsevier

    Dr Lukasz Kuryk, MBA

  59. 659. Oncolytic Adenovirus Loaded with Bioactive Modified Peptide as a Novel Approach to Treat Cancer

    Article • Molecular Therapy, May 2016, Elsevier

    Dr Lukasz Kuryk, MBA

  60. 661. Synergistic Anti-Tumor Efficacy of Immunogenic Adenovirus ONCOS-102 and Standard of Care Chemotherapy in Preclinical Mesothelioma Model

    Article • Molecular Therapy, May 2016, Elsevier

    Dr Lukasz Kuryk, MBA

  61. 642. Oncolytic Vaccines with Modified Tumor Epitopes for Cancer Immunotherapy

    Article • Molecular Therapy, May 2016, Elsevier

    Dr Lukasz Kuryk, MBA

  62. Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity

    Article • Molecular Cancer Therapeutics, February 2016, American Association for Cancer Research (AACR)

    Dr Lukasz Kuryk, MBA

  63. Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity

    Article • Molecular Therapy — Oncolytics, January 2016, Elsevier

    Dr Lukasz Kuryk, MBA

  64. Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma

    Article • OncoImmunology, October 2015, Taylor & Francis

    Dr Lukasz Kuryk, MBA

  65. 220. Evaluation of the Efficacy of a New Oncolytic Vaccine Platform in Humanized Mice

    Article • Molecular Therapy, May 2015, Elsevier

    Dr Lukasz Kuryk, MBA

  66. 622. Oncolytic Adenoviruses Loaded With Active Drugs as a Novel Drug Delivery System for Cancer Therapy

    Article • Molecular Therapy, May 2015, Elsevier

    Dr Lukasz Kuryk, MBA

  67. 71. Boosting the Immunogenicity of an Oncolytic Vaccinia Virus By Expression of DAI Can Enhance Anti-Tumor Immunity in Humanized Mice

    Article • Molecular Therapy, May 2015, Elsevier

    Dr Lukasz Kuryk, MBA

  68. 665. Toxicity and Bio-Distribution of a GM-CSF-Expressing, Chimeric Oncolytic Adenovirus ONCOS-102

    Article • Molecular Therapy, May 2015, Elsevier

    Dr Lukasz Kuryk, MBA

  69. Environmental Surveillance of Non-polio Enteroviruses in Poland, 2011

    Article • Food and Environmental Virology, April 2015, Springer Science + Business Media

    Dr Lukasz Kuryk, MBA

  70. Oncolytic adenoviruses coated with MHC-I tumor epitopes for a new oncolytic vaccine platform

    Article • Journal for ImmunoTherapy of Cancer, January 2015, Springer Science + Business Media

    Dr Lukasz Kuryk, MBA

  71. Innate Immunity to Adenovirus

    Article • Human Gene Therapy, April 2014, Mary Ann Liebert Inc

    Dr Lukasz Kuryk, MBA

  72. Genetic analysis of poliovirus strains isolated from sewage in Poland

    Article • Journal of Medical Virology, October 2013, Wiley

    Dr Lukasz Kuryk, MBA

  73. Killer viruses and immune-boosting drugs attack tumors near and far

    Article • Research Square

    Dr Lukasz Kuryk, MBA